Literature DB >> 29911912

Challenges of surgical management of intrahepatic cholangiocarcinoma.

Malcolm H Squires1, Jordan M Cloyd1, Mary Dillhoff1, Carl Schmidt1, Timothy M Pawlik1.   

Abstract

INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy arising from biliary tract epithelium within bile ducts proximal to the secondary biliary radicles. The majority of patients are diagnosed with locally advanced or metastatic disease at presentation. Surgical resection remains the only potentially curative option, but poses unique challenges due to the large size and aggressive behavior of these tumors. Areas covered: The goal of surgical management of iCCA is margin negative (R0) hepatic resection with preservation of adequate size liver remnant and function. Data regarding role of staging laparoscopy, margin status, portal lymphadenectomy, and vascular resection for iCCA are reviewed. Perioperative systemic therapy may have value, although prospective data have been lacking. Recurrence rates remain high even after R0 resection; among patients with recurrent disease limited to the liver, re-resection or locoregional therapies may play a role. Liver transplantation may be an option for select patients with very early-stage iCCA, although this should be done on a protocol-only basis. Expert commentary: Appropriate preoperative patient selection and surgical technique are paramount to ensure optimal oncologic outcomes for patients with resectable iCCA. Improving systemic and locoregional therapy options may help decrease recurrence rates and improve long-term survival for this aggressive malignancy.

Entities:  

Keywords:  Cholangiocarcinoma; bile duct; biliary tract cancer; intrahepatic; resection; surgery

Mesh:

Year:  2018        PMID: 29911912     DOI: 10.1080/17474124.2018.1489229

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  14 in total

1.  Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma.

Authors:  Grace C Lee; T Clark Gamblin; Zhi Ven Fong; Cristina R Ferrone; Lipika Goyal; Keith D Lillemoe; Lawrence S Blaszkowsky; Kenneth K Tanabe; Motaz Qadan
Journal:  Ann Surg Oncol       Date:  2019-07-31       Impact factor: 5.344

2.  Association Between Travel Distance, Hospital Volume, and Outcomes Following Resection of Cholangiocarcinoma.

Authors:  Eliza W Beal; Rittal Mehta; J Madison Hyer; Anghela Paredes; Katiuscha Merath; Mary E Dillhoff; Jordan Cloyd; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-02-27       Impact factor: 3.452

Review 3.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

4.  A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Br J Cancer       Date:  2022-01-25       Impact factor: 9.075

5.  The Landmark Series: Intrahepatic Cholangiocarcinoma.

Authors:  Jordan M Cloyd; Aslam Ejaz; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-05-17       Impact factor: 5.344

Review 6.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

Review 7.  A metastatic skull tumor from intrahepatic cholangiocarcinoma: A case report and literature review.

Authors:  Dawei Wang; Shiwei He; Liang Chu; Qing Chao; Qiujian Zhang; Hansheng Shu
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 8.  Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.

Authors:  Brinda Balasubramanian; Simran Venkatraman; Kyaw Zwar Myint; Tavan Janvilisri; Kanokpan Wongprasert; Supeecha Kumkate; David O Bates; Rutaiwan Tohtong
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-11

9.  Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma.

Authors:  Mingwen Jiao; Shanglei Ning; Jingbo Chen; Lili Chen; Meng Jiao; Zhonghui Cui; Lingyu Guo; Wentao Mu; Hui Yang
Journal:  Int J Oncol       Date:  2020-03-20       Impact factor: 5.650

10.  CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma.

Authors:  Weiyu Xu; Si Yu; Jianping Xiong; Junyu Long; Yongchang Zheng; Xinting Sang
Journal:  Aging (Albany NY)       Date:  2020-01-17       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.